Synairgen Partners with AstraZeneca to Advance its Lead Asthma Programme
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 8 (Table of Contents)
Published: 25 Aug-2014
DOI: 10.3833/pdr.v2014.i8.2053 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
AstraZeneca has licensed global rights to UK-based Synairgen’s SNG001, an inhaled form of interferon beta (IFN-beta) that is being developed for treating respiratory tract viral infections in patients with severe asthma and which also has potential in other pulmonary diseases, including chronic obstructive pulmonary disease...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS